ArticleJournal of inflammation research2025
Predicting Drug Resistance: The Use of Novel Inflammatory Markers in Identifying ESBL-Producing
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Extensively drug-resistant ESBL-producing enterobacterales and coexisting antimicrobial resistance genes are associated with mortality in critically ill patients with cancer.Scientific reports · 2026Article
- Performance evaluation of mNGS in pathogen diagnosis of skin and soft tissue infections and its optimization effect on antibiotic decision-making.Frontiers in cellular and infection microbiology · 2026Article
- Predicting Multidrug-Resistant Pneumonia: An Interpretable Machine Learning Model Validated in US and Chinese Patient Cohorts.Infection and drug resistance · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To explore the association of the Systemic Inflammatory Response Index (SIRI) and Systemic Inflammatory Immunity Index (SII) with extended-spectrum β-lactamase (ESBL)-producing Methods: A total of 425 patients with Results: SIRI and SII levels in the ESBL-producing group were significantly higher than those in the non-ESBL-producing group. Logistic regression analysis showed that the odds ratios for SIRI and SII were 1.092 and 1.158, respectively, with 95% confidence intervals of 1.001-1.115 and 1.015-1.204, respectively. The critical values for predicting ESBL-producing Conclusion: SIRI and SII are significantly associated with the risk of ESBL-producing
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.